Replies to post #11965 on GTC Biotherapeutics (fka GTCB)

[jessellivermore]

Viva Los Vegas.......

Back in Beantow (now known as "titletown"). My condolences to all the frowny faces.... Do not ask me why but IMHO there are are couple of more interested customers talking to you know what company (hint goats) and just maybe...........

":>)......

[Beerzoids]

Dew, you posted: "Importantly, Ovation will pay for all US-related clinical development of ATryn from this point forward (except as noted in #5 below)." ===

How will this reduce GTCB's cash burn rate going forward? How much of current "ongoing" expenditures might be effected by this deal?

Taking over costs, is just as good as milestone payments.

[quantumdot]

>5. If Leo’s phase-2 data in DIC are compelling, Ovation may decide to pursue both CABG/HR and DIC. However, if Ovation opts out of pursuing DIC, GTC will be free to partner the DIC indication with another company.<

Dew, do Ovation effectively have first right of refusal on all ATryn applications in US now? If so it seems like a very cheap call option.

[alertmeipp]

Dew, how much upfront would FoB deals bring? TIA

[shears]

Pardon my being out of commission for a while and if this question has been answered before I apologize. Do we have any idea how much of the milestone $248M is for non-HD related activity? In other words could we expect additional future milestone payments beyond this sum for the acquired indications?